Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Disease Pathology and Progression.

ABSTRACT: Lewy body dementia (LBD), which encompasses Parkinson's disease dementia (PDD) and Dementia with Lewy bodies (DLB), currently lacks established biofluid markers reflective of its complex molecular pathophysiology. Multiplex proteomic tools, such as the recently released NUcleic acid Linked ImmunoSandwich Assay (NULISA^™), can simultaneously assess a diverse array of neurodegenerative targets and address this critical biomarker gap. We used the NULISA CNS disease panel to analyze 852 baseline and longitudinal cerebrospinal fluid (CSF) samples from control, PD without cognitive impairment (PD-NCI), PD with cognitive impairment (PD-CI), DLB, and Alzheimer's disease (AD) subjects. A subset of control and DLB cases also had alpha-synuclein seed amplification assay (αSyn-SAA) results.

SUBMITTER: Higginbotham L 

PROVIDER: S-EPMC12259125 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature